Stocktoria
Coherus Oncology, Inc. CHRS
Nasdaq · XNAS · stock · Biological Products, (No Diagnostic Substances) · website · IPO 2014-11-06
Coherus Oncology, Inc. financials (annual, from 10-K)
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | $42.2M | $26.4M | $257.2M | $211.0M | $326.6M |
| R&D expense | $108.9M | $91.8M | $109.4M | $199.4M | $363.1M |
| SG&A expense | $100.6M | $125.5M | $192.0M | $198.5M | $169.7M |
| Operating income | -$181.1M | -$199.7M | -$203.2M | -$256.9M | -$263.9M |
| Interest expense | $9.0M | $10.7M | $40.5M | $32.5M | $23.0M |
| Income tax | $0 | $0 | -$380,000 | $0 | $0 |
| Net income | $168.0M | $28.5M | -$237.9M | -$291.8M | -$287.1M |
| EPS (diluted) | $1.43 | $0.25 | $-2.53 | $-3.76 | $-3.81 |
| Operating cash flow | -$138.5M | -$20.4M | -$174.9M | -$241.1M | -$37.4M |
| Free cash flow | — | — | -$175.2M | -$243.2M | -$38.7M |
| Cash & equivalents | $88.9M | $126.0M | $102.9M | $63.5M | $417.2M |
| Inventory | $3.2M | $4.2M | $62.6M | $38.8M | $37.6M |
| Total assets | $258.3M | $448.5M | $629.6M | $480.8M | $679.3M |
| Total liabilities | $197.3M | $580.5M | $823.0M | $618.3M | $581.6M |
| Shareholders' equity | $61.0M | -$132.0M | -$193.4M | -$137.4M | $97.7M |
Source: SEC EDGAR filings · CIK 0001512762 · as of 2025-12-31. Facts from filings plus Stocktoria's own computed scores — not investment advice.